Trump plans to impose tariffs on semiconductors and pharmaceuticals.

On April 14,40 Foreign Exchange Platforms Publicly Announced the U.S. Trump administration announced it has initiated an investigation led by the Department of Commerce, marking a significant step towards imposing tariffs on semiconductor and pharmaceutical imports. This investigation could represent a new phase of a comprehensive trade war under the Trump administration, aiming to assess the impact of these imports on U.S. national security.

According to two notices published by the U.S. Department of Commerce in the Federal Register, the investigation will focus on the potential threats to U.S. national security posed by “imported semiconductors and semiconductor manufacturing equipment” as well as “pharmaceuticals and drug ingredients, including finished drugs.” These measures lay the groundwork for potential future tariffs and further escalate tensions between the U.S. and its global trading partners.

Currently, the U.S. is engaged in trade disputes with multiple economies worldwide, and this decision by the Trump administration might extend its tariff policies into technology and pharmaceutical sectors. If ultimately implemented, it could have profound effects on the semiconductor and pharmaceutical industries, especially considering the global supply chains are highly dependent on these products. As the investigation progresses, the trade situation in the coming months is expected to become more complex.

This move indicates that the Trump administration is not only taking a tough stance on foreign economic policy but also intends to tighten control over key industries involving national security.

The market carries risks, and investment should be cautious. This article does not constitute personal investment advice and has not taken into account individual users' specific investment goals, financial situations, or needs. Users should consider whether any opinions, viewpoints, or conclusions in this article are suitable for their particular circumstances. Investing based on this is at one's own responsibility.